Thông tin thuốc gốc
Chỉ định và Liều dùng
Chronic hepatitis C
Adult: In patient with chronic hepatitis C genotype 1 or 4 with compensated liver disease: 150 mg once daily, in combination with other antivirals. Treatment duration varies according to regimen used.
Suy gan
Moderate or severe (Child-Pugh class B or C): Not recommended.
Chống chỉ định
Hypersensitivity. Concomitant use with CYP3A4 inducers or inhibitors.
Thận trọng
Patient with hepatitis B virus (HBV) infection, decompensated cirrhosis. Moderate to severe hepatic impairment. Not intended for use as monotherapy. Pregnancy and lactation.
Tác dụng không mong muốn
Significant: Photosensitivity, rash, pruritus.
Blood and lymphatic system disorders: Hyperbilirubinaemia.
Gastrointestinal disorders: Nausea, diarrhoea, constipation.
General disorders and administration site conditions: Fatigue.
Musculoskeletal and connective tissue disorders: Myalgia.
Nervous system disorders: Headache, dizziness.
Psychiatric disorders: Insomnia.
Respiratory, thoracic and mediastinal disorders: Dyspnoea.
Potentially Fatal: Hepatitis B virus reactivation, resulting in fulminant hepatitis or hepatic failure (in patients with HBV co-infection); hepatic decompensation and hepatic failure, symptomatic bradycardia.
Thông tin tư vấn bệnh nhân
May impair ability to drive or operate machinery.
Chỉ số theo dõi
Monitor CBC, INR, LFT, serum creatinine, HCV-RNA at baseline and during therapy. Obtain hepatitis B surface antigen (HbsAg) and hepatitis B core antibody (anti-HBc) prior to initiation of therapy to test for evidence of current or prior HBV infection. Perform pregnancy test and ensure proper use of birth control prior to therapy.
Tương tác
Increased plasma concentration with antiarrhythmic agents (e.g. disopyramide, flecainide, mexiletine). Increased anticoagulant effect of warfarin.
Potentially Fatal: Decreased plasma concentration and therapeutic effect with moderate or strong CYP3A4 inducers (e.g. carbamazepine, phenobarbital, phenytoin, rifampicin). Increased plasma levels with moderate or potent CYP3A4 inhibitors (e.g. ketoconazole). May increase the concentrations of P-glycoprotein substrates (e.g. doxorubicin), organic anion transport polypeptides, ciclosporin. May cause symptomatic bradycardia when given with amiodarone.
Tương tác với thức ăn
Increased absorption with food. Decreased serum concentration with St John’s wort. Increased serum concentration with milk thistle.
Tác dụng
Description: Simeprevir is a hepatitis C virus (HCV) nonstructural protein 3/4A (NS3/4A) serine protease inhibitor. It binds to the NS3/4A protease active site, thereby inhibiting viral replication activity.
Absorption: Increased absorption with food. Bioavailability: 62%. Time to peak plasma concentration: 4-6 hr.
Distribution: Plasma protein binding: >99.9%, to albumin and α1-acid glycoprotein.
Metabolism: Undergoes oxidative metabolism in the liver mainly by CYP3A4 enzyme, to unchanged drug and metabolites.
Excretion: Mainly via faeces (approx 91%); urine (<1%). Terminal elimination half-life: 41 hours.
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Simeprevir, CID=24873435, (accessed on Jan. 23, 2020)

Bảo quản
Store below 30°C. Protect from light.
Any unused portions should be disposed of in accordance with local requirements.
Phân loại MIMS
Thuốc kháng virus
Phân loại ATC
J05AP05 - simeprevir ; Belongs to the class of antivirals for treatment of HCV infections. Used in the treatment of hepatitis C viral infections.
Tài liệu tham khảo
Anon. Simeprevir. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 01/02/2018.

Buckingham R (ed). Simeprevir. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 01/02/2018.

Joint Formulary Committee. Simeprevir. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 01/02/2018.

McEvoy GK, Snow EK, Miller J et al (eds). Simeprevir Sodium. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 01/02/2018.

Olysio Capsule (Janssen Products LP). DailyMed. Source: U.S. National Library of Medicine. Accessed 01/02/2018.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Simeprevir từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in